关键词: 脑梗死; 颈动脉疾病; 阿托伐他汀; 基质金属蛋白酶-9

Abstract: Objective To observe the influence of atorvastatin on serum matrix metalloproteinases-9(MMP-9)in patients with acute cerebral infarction.Methods One hundred and twenty-eight patients with acute cerebral infarction in anteriorcirculation were divided into three subgroups according to the characteristic of carotid arteriesatherosclerotic(AS) plaques, which were assessed by color doppler ultrasonography:stable plaquegroup(51 cases), vulnerable plaque group(46 cases) and no plaque group(31 cases). All patientsreceived oral atorvastatin of 20 mg daily for 2 weeks. The levels of serum MMP-9 before and aftertreatment in patients were measured respectively. Statistic analysis was performed with SPSS11.5.Results ①The level of serum MMP-9 in vulnerable plaque group was (419.93±113.12)μg/L and in stable plaque group was (271.45±80.34)μg/L before the treatment, it was significantlyhigher than (147.36±23.62)μg/L in no plaque group, and the level in vulnerable plaque groupwas also significantly higher than in stable plaque group(P <0.01, respectively). ②At the end ofthe two weeks after treatment with atorvastatin, the level of serum MMP-9 in three groups were(242.58±101.63)μg/L, (191.36±79.28) μg/L and (126.72±22.86)μg/L, it was significantly lowerthan the level in the same group before treatment (P <0.01, respectively).Conclusion The level of the serum MMP-9 in patients with acute cerebral infarction in anteriorcirculation is associated with the occurrence and stability of the carotid atherosclerosis plaques;Atorvastatin has effects on a marked reduction in MMP-9 level in patients with acute cerebralinfarction in anterior circulation.

Key words: Brain infarction; Carotid artery diseases; Atorvastatin; Matrix metalloproteinase-9